{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T09:47:47Z","timestamp":1775123267959,"version":"3.50.1"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>A 58-year-old man with previous melanoma of the left leg underwent whole-body <jats:sup>18<\/jats:sup>F-FDG PET\/CT to stage metastatic disease prior to commencing pembrolizumab. Follow-up FDG PET\/CT after 3 months of treatment showed partial metabolic response of soft tissue and nodal metastases and diffuse increased thyroid and colonic uptake, suggestive of thyroiditis and colitis. Pembrolizumab was ceased, and a repeat FDG PET\/CT scan showed regression of uptake in the thyroid gland and colon, in keeping with resolution of inflammatory change. Immune-related adverse events induced by Immune checkpoint inhibitors, such as pembrolizumab, should be recognized\u2014cessation of treatment often leads to resolution.<\/jats:p>","DOI":"10.1097\/rlu.0000000000003306","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T21:25:14Z","timestamp":1601501114000},"page":"e121-e122","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Pembrolizumab-Induced Thyroiditis and Colitis\u2014Presentation and Resolution on Serial FDG PET\/CT"],"prefix":"10.1097","volume":"46","author":[{"given":"Ayah Adel","family":"Nawwar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Searle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iain Douglas","family":"Lyburn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,9,23]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/ITT.S141577","article-title":"Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events","volume":"6","year":"2017","journal-title":"ImmunoTargets Ther"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2214\/AJR.14.13575","article-title":"18F-FDG PET\/CT and melanoma: staging, immune modulation and mutation-targeted therapy assessment, and prognosis","volume":"205","year":"2015","journal-title":"Am J Roentgenol"},{"key":"bib3-20250621","first-page":"61","article-title":"Immunotherapy of melanoma","volume":"2","year":"2017","journal-title":"Wspolczesna Onkol"},{"key":"bib4-20250621","first-page":"76","article-title":"Managing immune checkpoint\u2013blocking antibody side effects","year":"2015","journal-title":"Am Soc Clin Oncol Educ B"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/apt.13281","article-title":"Systematic review: colitis associated with anti\u2013CTLA-4 therapy","volume":"42","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","year":"2017","journal-title":"Front Pharmacol"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","year":"2015","journal-title":"N Engl J Med"},{"key":"bib8-20250621","first-page":"212515","article-title":"Treatment with combined dabrafenib and trametinib in BRAFV600E-mutated metastatic malignant melanoma: a case of long-term complete response after treatment cessation","volume":"7","year":"2018","journal-title":"Drugs Context"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","year":"2017","journal-title":"Ann Oncol"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1634\/theoncologist.2016-0055","article-title":"Management of adverse events following treatment with anti\u2013programmed death-1 agents","volume":"21","year":"2016","journal-title":"Oncologist"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003306","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T21:05:54Z","timestamp":1750539954000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,23]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003306","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,23]]}}}